Keynote review: Allosterism in membrane receptors

Drug Discovery Today

Volumn 11, Issue 5-6, 2006, Pages 191-202

  Gao, Zhan Guo ^a,b,c   Jacobson, Kenneth A ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERIC REGULATION; ANIMALS; DIMERIZATION; HUMANS; LIGANDS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, METABOTROPIC GLUTAMATE; RHODOPSIN; SECRETIN;

EID: 33645360875     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03689-5     Document Type: Review

References (148)

1. Monod J. On the nature of allosteric transitions: a plausible model J. Mol. Biol. 12 1965 88 118
2. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery Nat. Rev. Drug Discov. 1 2002 198 210
3. Changeux J.P., Edelstein S.J. Allosteric mechanisms of signal transduction Science 308 2005 1424 1428
4. Bohr C. Ubereinen in biologischen Beziehung wichtigen Einfluss, den die Kohlen-sauerspannung des Blütes auf dessen Sauerstoffbindung ubt Skand. Arch. Physiol. 15 1904 401 412
5. Changeux J.P. On the cooperativity of biological membranes Proc. Natl. Acad. Sci. U. S. A. 57 1967 335 341
6. Macdonald R.L., Olsen R.W. GABAA receptor channels Annu. Rev. Neurosci. 17 1994 569 602
7. Bullock R. Galantamine: use in Alzheimer's disease and related disorders Expert Rev. Neurother. 4 2004 153 163
8. Poon G. Cinacalcet hydrochloride (Sensipar) Proc. (Bayl. Univ. Med. Cent.) 18 2005 181 184
9. Lindberg J.S. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J. Am. Soc. Nephrol. 16 2005 800 807
10. Palczewski K. Crystal structure of rhodopsin: a G protein-coupled receptor Science 289 2000 739 745
11. Pin J.P. Allosteric functioning of dimeric class C G-protein-coupled receptors FEBS J. 272 2005 2947 2955
12. George S.R. G-protein-coupled receptor oligomerization and its potential for drug discovery Nat. Rev. Drug Discov. 1 2002 808 820
13. Chabre M., le Maire M. Monomeric G-protein-coupled receptor as a functional unit Biochemistry 44 2005 9395 9403
14. Terrillon S., Bouvier M. Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes EMBO J. 23 2004 3950 3961
15. Bulenger S. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation Trends Pharmacol. Sci. 26 2005 131 137
16. Pin J.P. Activation mechanism of the heterodimeric GABAB receptor Biochem. Pharmacol. 68 2004 1565 1572
17. Nelson G. An amino-acid taste receptor Nature 416 2002 199 202
18. Birdsall N.J., Lazareno S. Allosterism at muscarinic receptors: ligands and mechanisms Mini Rev. Med. Chem. 5 2005 523 543
19. Gao Z.G. Allosteric modulation of the adenosine family of receptors Mini Rev. Med. Chem. 5 2005 545 553
20. Schetz J.A. Allosteric modulation of dopamine receptors Mini Rev. Med. Chem. 5 2005 555 561
21. Hoare S.R. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors Drug Discov. Today 10 2005 417 427
22. Soudijn W. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments Drug Discov. Today 9 2004 752 758
23. Trankle C. Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M (2) receptors Mol. Pharmacol. 56 1999 962 965
24. Hall D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation Mol. Pharmacol. 58 2000 1412 1423
25. Price M.R. Allosteric modulation of the cannabinoid CB1 receptor Mol. Pharmacol. 68 2005 1484 1495
26. Ehlert F.J. Analysis of allosterism in functional assays J. Pharmacol. Exp. Ther. 315 2005 740 754
27. Bruns R.F., Fergus J.H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes Mol. Pharmacol. 38 1990 939 949
28. van der Klein P.A. Allosteric modulation of the adenosine A1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding J. Med. Chem. 42 1999 3629 3635
29. Tranberg C.E. 2-Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors J. Med. Chem. 45 2002 382 389
30. Li X. Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain Pain 97 2002 117 125
31. Li X. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism J. Pharmacol. Exp. Ther. 305 2003 950 955
32. Figler H. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract guanine nucleotide effects on agonist binding Mol. Pharmacol. 64 2003 1557 1564
33. Lanzafame A., Christopoulos A. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors J. Pharmacol. Exp. Ther. 308 2004 830 837
34. Fawzi A.B. SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors Mol. Pharmacol. 59 2001 30 37
35. Göblyös A. Synthesis and biological evaluation of a new series of 2,3,5-substituted [1,2,4]-thiadiazoles as modulators of adenosine A1 receptors and their molecular mechanism of action J. Med. Chem. 48 2005 1145 1151
36. Gao Z.G., IJzerman A.P. Allosteric modulation of A2A adenosine receptors by amiloride analogues and sodium ions Biochem. Pharmacol. 60 2000 669 676
37. Gao Z.G. Allosteric modulation of A3 adenosine receptors by a series of 3-(2-pyridinyl) isoquinoline derivatives Mol. Pharmacol. 60 2001 1057 1063
38. Gao Z.G. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives Mol. Pharmacol. 62 2002 81 89
39. Gao Z.G. Identification of essential residues involved in the allosteric modulation of the human A3 adenosine receptor Mol. Pharmacol. 63 2003 1021 1031
40. Sur C., Kinney G.G. Selective targeting of muscarinic receptors: novel therapeutic approaches for psychotic disorders Curr. Neuropharmacol. 3 2005 63 71
41. Lullmann H. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds Eur. J. Pharmacol. 6 1969 241 247
42. Clark A.J., Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors Br. J. Pharmacol. 58 1976 323 331
43. Stockton J.M. Modification of the binding properties of muscarinic receptors by gallamine Mol. Pharmacol. 23 1983 551 557
44. Trankle C. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors Mol. Pharmacol. 64 2003 180 190
45. Muth M. Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents J. Med. Chem. 48 2005 2212 2217
46. Spalding T.A. Discovery of an ectopic activation site on the M1 muscarinic receptor Mol. Pharmacol. 61 2002 1297 1302
47. Langmead C.J. Probing the molecular mechanism of interaction between AC-42 and the muscarinic M1 receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist Mol. Pharmacol. 69 2006 236 246
48. Sur C. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity Proc. Natl. Acad. Sci. U. S. A. 100 2003 13674 13679
49. Tahtaoui C. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor J. Med. Chem. 47 2004 4300 4315
50. Birdsall N.J. Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies Mol. Pharmacol. 55 1999 778 786
51. Lazareno S. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors Mol. Pharmacol. 62 2002 1492 1505
52. Lazareno S. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity Mol. Pharmacol. 65 2004 257 266
53. Felder C.C. Pharmacological and molecular characterisation of a positive allosteric modulator selective for the muscarinic M4 receptor being developed for the treatment of psychosis Neuropsychopharmacol. 29 2004 S115
54. Trankle C. Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors Mol. Pharmacol. 68 2005 1597 1610
55. Wess J. Allosteric binding sites on muscarinic acetylcholine receptors Mol. Pharmacol. 68 2005 1506 1509
56. Fisher A. Design and synthesis of photoaffinity-labeling ligands of the L-prolyl- L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor J. Med. Chem. 49 2006 307 317
57. Holst B. Non-peptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling Mol. Endocrinol. 19 2005 2400 2411
58. White F.A. Chemokines: integrators of pain and inflammation Nat. Rev. Drug Discov. 4 2005 834 844
59. Bendall L. Chemokines and their receptors in disease Histol. Histopathol. 20 2005 907 926
60. Sachpatzidis A. Identification of allosteric peptide agonists of CXCR4 J. Biol. Chem. 278 2003 896 907
61. Bertini R. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury Proc. Natl. Acad. Sci. U. S. A. 101 2004 11791 11796
62. Watson C. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor Mol. Pharmacol. 67 2005 1268 1282
63. Waugh D.J. Binding, partial agonism, and potentiation of alpha (1)-adrenergic receptor function by benzodiazepines: a potential site of allosteric modulation J. Pharmacol. Exp. Ther. 291 1999 1164 1171
64. Sharpe I.A. Allosteric alpha 1-adrenoreceptor antagonism by the conopeptide rho-TIA J. Biol. Chem. 278 2003 34451 34457
65. Im W.B. Positive allosteric modulator of the human 5-HT2C receptor Mol. Pharmacol. 64 2003 78 84
66. Spedding M. Antagonists and the purinergic nerve hypothesis: 2, 2 (-pyridylisatogen tosylate (PIT), an allosteric modulator of P2Y receptors. A retrospective on a quarter century of progress J. Auton. Nerv. Syst. 81 2000 225 227
67. Gao Z.G. 2,2 (-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding Biochem. Pharmacol. 68 2004 231 237
68. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function, and regulation Physiol. Rev. 81 2001 629 683
69. Leggett J.D. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors Br. J. Pharmacol. 141 2004 253 262
70. Hoare S.R. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists Mol. Pharmacol. 63 2003 751 765 Erratum in: Mol Pharmacol. 2005 68, 260
71. Liaw C.W. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors Mol. Endocrinol. 11 1997 2048 2053
72. Cascieri M.A. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor J. Biol. Chem. 274 1999 8694 8697
73. Katayama T. Discovery of a non-peptide small molecule that selectively mimics the biological actions of calcitonin Biochim. Biophys. Acta 1526 2001 183 190
74. Teng, M. et al. (2000) Nonpeptide GLP-1 agonists. WO 00/42026
75. Zobel A.W. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated J. Psychiatr. Res. 34 2000 171 181
76. Olesen J. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine N. Engl. J. Med. 350 2004 1104 1110
77. Petersen K.F., Sullivan J.T. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans Diabetologia 44 2001 2018 2024
78. Binet V. Molecular mechanisms of GABAB receptor activation: new insights from the mechanism of action of CGP7930, a positive allosteric modulator Biochem. Soc. Trans. 32 2004 871 872
79. Carroll F.Y. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity Mol. Pharmacol. 59 2001 965 973
80. Goudet C. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors Proc. Natl. Acad. Sci. U. S. A. 101 2004 378 383
81. Jiang P. The cysteine-rich region of T1R3 determines responses to intensely sweet proteins J. Biol. Chem. 279 2004 45068 45075
82. Hu J. Human Ca2+ receptor cysteine-rich domain. Analysis of function of mutant and chimeric receptors J. Biol. Chem. 275 2000 16382 16389
83. Shipe W.D. Recent advances in positive allosteric modulators of metabotropic glutamate receptors Curr. Opin. Drug Discov. Devel. 8 2005 449 457
84. Layton M.E. Subtype-selective noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1) Curr. Top. Med. Chem. 5 2005 859 867
85. Rudd M.T., McCauley J.A. Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2) Curr. Top. Med. Chem. 5 2005 869 884
86. Marino M.J. Targeting the metabotropic glutamate receptor mGluR4 for the treatment of diseases of the central nervous system Curr. Top. Med. Chem. 5 2005 885 895
87. Williams D.L. Jr, Lindsley C.W. Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5) Curr. Top. Med. Chem. 5 2005 825 846
88. Niswender C.M. New therapeutic frontiers for metabotropic glutamate receptors Curr. Top. Med. Chem. 5 2005 847 857
89. Litschig S. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding Mol. Pharmacol. 55 1999 453 461
90. Gasparini F. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacology 38 1999 1493 1503
91. Kew J.N. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential Pharmacol. Ther. 104 2004 233 244
92. Johnson M.P. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2- methoxyphenoxy) phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethylamine J. Med. Chem. 46 2003 3189 3192
93. Pinkerton A.B. Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor J. Med. Chem. 47 2004 4595 4599
94. Marino M.J. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment Proc. Natl. Acad. Sci. U. S. A. 100 2003 13668 13673
95. O'Brien J.A. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol. Pharmacol. 64 2003 731 740
96. O'Brien J.A. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain J. Pharmacol. Exp. Ther. 309 2004 568 577
97. Kinney G.G. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 313 2005 199 206
98. Govek S.P. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): Efficacy in an animal model for schizophrenia Bioorg. Med. Chem. Lett. 15 2005 4068 4072
99. Grillon C. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans Psychopharmacology (Berl.) 168 2003 446 454
100. Kellner M. Effects of a metabotropic glutamate (2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results Psychopharmacology (Berl.) 179 2005 310 335
101. Nemeth E.F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc. Natl. Acad. Sci. U. S. A. 95 1998 4040 4045
102. Hu J. Identification of the acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator J. Biol. Chem. 29 2002 46622 46631
103. Petrel C. Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain J. Biol. Chem. 279 2004 18990 18997
104. Conigrave A.D. L-amino acid sensing by the extracellular Ca2+-sensing receptor Proc. Natl. Acad. Sci. U. S. A. 97 2000 4814 4819
105. Mun H.C. The Venus Fly Trap domain of the extracellular Ca2+-sensing receptor is required for L-amino acid sensing J. Biol. Chem. 279 2004 51739 51744
106. Nemeth E.F. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone J. Pharmacol. Exp. Ther. 299 2001 323 331
107. Petrel C. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor J. Biol. Chem. 278 2003 49487 49494
108. Hu J. A cluster of naturally occurring, activating mutations identifies a region in the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ J. Biol. Chem. 280 2005 5113 5120
109. Arey B.J. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo Endocrinology 146 2005 2015 2022
110. Mooser G. Sodium and potassium salt stimulation of taste receptor cells: an allosteric model Proc. Natl. Acad. Sci. U. S. A. 77 1980 1686 1690
111. Nakamura M., Kurihara K. Canine taste nerve responses to monosodium glutamate and disodium guanylate: differentiation between umami and salt components with amiloride Brain Res. 541 1991 21 28
112. Kurihara K., Kashiwayanagi M. Introductory remarks on umami taste Ann. N. Y. Acad. Sci. 855 1998 393 397
113. Adler E. A novel family of mammalian taste receptors Cell 100 2000 693 702
114. Changeux J.P., Edelstein S.J. Allosteric receptors after 30 years Neuron 21 1998 959 980
115. Hogg R.C. Allosteric modulation of ligand-gated ion channels Biochem. Pharmacol. 70 2005 1267 1276
116. Alexander K. Allosteric modulation and accelerated resensitization of human P2X3 receptors by cibacron blue J. Pharmacol. Exp. Ther. 291 1999 1135 1142
117. + on rat DRG neurons in culture Neuropharmacology 44 2003 132 140
118. Jarvis M.F. Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X (3) allosteric modulator, cibacron blue Br. J. Pharmacol. 132 2001 259 269
119. Liang S.D. Tetramethylpyrazine inhibits ATP-activated currents in rat dorsal root ganglion neurons Brain Res. 1040 2005 92 97
120. Weight F.F. Alcohol action on membrane ion channels gated by extracellular ATP (P2X receptors) Neurochem. Int. 35 1999 143 152
121. Khakh B.S. Allosteric control of gating and kinetics at P2X4 receptor channels J. Neurosci. 19 1999 7289 7299
122. Nagaya N. An intersubunit zinc binding site in rat P2X2 receptors J. Biol. Chem. 280 2005 25982 25993
123. Kennedy C. P2X receptors: targets for novel analgesics? Neuroscientist 11 2005 345 356
124. Mayer M.L. Glutamate receptor ion channels Curr. Opin. Neurobiol. 15 2005 282 288
125. Rachline J. The micromolar zinc-binding domain on the NMDA receptor subunit NR2B J. Neurosci. 25 2005 308 317
126. Kloda A. Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-D-aspartate receptors Mol. Pharmacol. 65 2004 1386 1396
127. Bateson A.N. The benzodiazepine site of the GABAA receptor: an old target with new potential? Sleep Med. 5 2004 S9 S15
128. Rudolph U. Benzodiazepine actions mediated by specific gamma-aminobutyric acidA receptor subtypes Nature 401 1999 796 800
129. Whiting P.J. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov. Today 8 2003 445 450
130. Street L.J. Synthesis and biological evaluation of 3-heterocyclyl-7,8,9, 10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA (A) alpha5 benzodiazepine binding site J. Med. Chem. 47 2004 3642 3657
131. Hogg R.C., Bertrand D. Nicotinic acetylcholine receptors as drug targets Curr. Drug Targets CNS Neurol. Disord. 3 2004 123 130
132. Samochocki M. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR Acta Neurol. Scand. Suppl. 176 2000 68 73
133. Texido L. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity Br. J. Pharmacol. 145 2005 672 678
134. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy N. Engl. J. Med. 353 2005 172 187
135. Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors J. Biol. Chem. 270 1995 3068 3073
136. Van Obberghen E. Signalling through the insulin receptor and the insulin-like growth factor-I receptor Diabetologia 37 1994 S125 S134
137. He X.L., Garcia K.C. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75 Science 304 2004 870 875
138. Lu B. The yin and yang of neurotrophin action Nat. Rev. Neurosci. 6 2005 603 614
139. Zaccaro M.C. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains J. Biol. Chem. 276 2001 31023 31029
140. Wilkie N. The non-peptidyl fungal metabolite L-783,281 activates TRK neurotrophin receptors J. Neurochem. 78 2001 1135 1145
141. Pollack S.J., Harper S.J. Small molecule Trk receptor agonists and other neurotrophic factor mimetics Curr. Drug Targets CNS Neurol. Disord. 1 2002 59 80
142. Farooqui T. Ganglioside GM1 enhances induction by nerve growth factor of a putative dimer of TrkA J. Neurochem. 68 1997 2348 2355
143. Lazareno S. Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-3H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site Mol. Pharmacol. 58 2000 194 207
144. Pollack S. The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor Mol. Pharmacol. 56 1999 185 195
145. Padayatti P.S. Structural insights into the regulation and the activation mechanism of mammalian guanylyl cyclases Pharmacol. Ther. 104 2004 83 99
146. Martin E. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components Proc. Natl. Acad. Sci. U. S. A. 98 2001 12938 12942
147. Stasch J.P. NO-independent regulatory site on soluble guanylate cyclase Nature 410 2001 212 215
148. Stasch J.P. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle Br. J. Pharmacol. 136 2002 773 783